Detalhe da pesquisa
1.
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
Haematologica;
108(7): 1793-1802, 2023 Jul 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36779592
2.
PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation.
Arterioscler Thromb Vasc Biol;
38(2): 448-456, 2018 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29269513
3.
First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects.
Br J Clin Pharmacol;
84(5): 876-887, 2018 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29346838
4.
A Phase I, Randomized, Multi-Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants.
Clin Pharmacol Ther;
115(5): 1075-1084, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38159266
5.
Supramolecular recognition enhanced electrochemical sensing: ß-cyclodextrin and Pd nanoparticle co-decorated 3D reduced graphene oxide nanocomposite-modified glassy carbon electrode for the quantification of ractopamine.
Anal Methods;
15(30): 3642-3649, 2023 08 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37475678
6.
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study.
Lancet Haematol;
10(11): e902-e912, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37914483
7.
Microwave biochars produced with activated carbon catalyst: Characterization and sorption of volatile organic compounds (VOCs).
Sci Total Environ;
827: 153996, 2022 Jun 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35189217
8.
Step scheme nickel-aluminium layered double hydroxides/biochar heterostructure photocatalyst for synergistic adsorption and photodegradation of tetracycline.
Chemosphere;
309(Pt 2): 136802, 2022 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36220437
9.
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Target Oncol;
17(4): 433-439, 2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35749004
10.
Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy.
CPT Pharmacometrics Syst Pharmacol;
10(8): 839-850, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34085779
11.
ß-Cyclodextrinâ»Hyaluronic Acid Polymer Functionalized Magnetic Graphene Oxide Nanocomposites for Targeted Photo-Chemotherapy of Tumor Cells.
Polymers (Basel);
11(1)2019 Jan 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30960117
12.
Applications of high throughput microsomal stability assay in drug discovery.
Comb Chem High Throughput Screen;
11(6): 469-76, 2008 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18673274
13.
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Target Oncol;
17(5): 609, 2022 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35913648
14.
UHPLC-MS/MS bioanalysis of urinary DHEA, cortisone and their hydroxylated metabolites as potential biomarkers for CYP3A-mediated drug-drug interactions.
Bioanalysis;
8(23): 2429-2443, 2016 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27855510
15.
Transformation of heavy metal speciation during sludge drying: mechanistic insights.
J Hazard Mater;
265: 96-103, 2014 Jan 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24342049
16.
[Quantitative partitioning of soil selenium in the selenium-rich area of Northern Zhejiang Plain].
Huan Jing Ke Xue;
34(7): 2775-81, 2013 Jul.
Artigo
em Zh
| MEDLINE
| ID: mdl-24028012
17.
Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist.
Int Immunopharmacol;
17(2): 178-83, 2013 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23791619
18.
[Drying characteristics and apparent change of sludge granules during drying].
Huan Jing Ke Xue;
32(8): 2358-64, 2011 Aug.
Artigo
em Zh
| MEDLINE
| ID: mdl-22619963